IDH1 and glioma: The IDH1 mutation rate was higher in NI subgroup II (82%) than NI subgroup I (36%), IDH1 mutation dramatically indicated the outcome of glioma patients, so the distinction in IDH1 mutation between two cluster subgroups may contribute to the prognosis of glioma.